Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2021

View Archived Issues

Restored ciliogenesis switches glioma stem cells from self-renewal to differentiation

GSK-852 identified as a soluble BET inhibitor selective for BD2

CHIR-99021 acts as mitochondrial function enhancer and shows activity in models of HD

Medshine Discovery identifies new S1PR1 agonists

Sironax describes new ferroptosis inhibitors

Ennovabio, Shanghai Ennova Biopharmaceutical patent MAP4K1 inhibitors

New CDK12 inhibitors presented by Bayer, Deutsches Krebsforschungszentrum

CD147 as therapeutic target against SARS-CoV-2 and its variants

Model of CDNF gene inactivation points to possible therapies for Parkinson's disease

VBI reports new preclinical data on COVID-19 vaccine candidates VBI-2902, VBI-2905 and VBI-2901

ER-001259851-000, novel selective Axl inhibitor with promising PK profile in vivo

GlaxoSmithKline compounds may illuminate TAF1 (BD2) potential as a therapeutic target

Mindset identifies MSP-4019 and MSP-4020 from Family 4 compounds

BetterLife Pharma reports neurological receptor binding data for TD-0148A

Bioartificial implant delivers anticytokine drugs in response to dynamic biological signals

Vaxil offers update on research and development activities

IDH1 mutations affect antitumor immunity in glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...